Close Menu

NEW YORK – Molecular analysis firm Aegea Biotechnologies announced Tuesday it has entered into a collaboration agreement with Tauriga Sciences to develop a rapid multiplexed PCR-based test for SARS-CoV-2.

The test, which is being developed by Aegea, will be designed "to have superior sensitivity and selectivity," and will measure the virus from nasal or other swabs, the companies said. The test will also use Aegea's technologies, which can detect targets with single-nucleotide resolution, to differentiate between different strains of the virus.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.